Versamune is PDS Biotechnology's proprietary T-cell activating platform technology, with PDS0101 as its lead therapeutic cancer vaccine candidate targeting HPV16-positive cancers. PDS0101 showed strong Phase 2 data — a 39.3-month median overall survival when combined with pembrolizumab in first-line head and neck cancer, well above the standard-of-care benchmark. However, in August 2026, PDS Biotech discontinued internal investment in the PDS0101 Phase 3 VERSATILE-003 trial due to cash constraints and pivoted to prioritize PDS0301. The company is now seeking a strategic partnership for PDS0101. With severe liquidity (~$5.6M cash), a Nasdaq deficiency notice, and no hard catalyst scheduled for Versamune/PDS0101, the drug's path forward depends entirely on finding a partner.
Zervimesine (CT1812) is Cognition Therapeutics' lead drug candidate, a sigma-2 receptor antagonist in development for dementia with Lewy bodies (DLB) psychosis — a neurodegenerative condition affecting ~1.4 million Americans with no FDA-approved treatments. Phase 2 SHIMMER data showed an 86% slowing of neuropsychiatric decline vs placebo, and the FDA has aligned on a Phase 3 registrational trial design (October 2026). The stock trades at ~$0.72 with a ~$71M market cap, with 8 of 9 analysts rating it Buy/Strong Buy and a mean price target of $3.33 (~317% upside). However, the company is pre-revenue with ~$37M cash (runway through Q2 2027), and the Phase 3 trial has not yet begun. The earlier PDUFA date (April 2026) for Alzheimer's disease passed without a clear outcome, and the company pivoted to the DLB psychosis indication where the regulatory path is now clearer.
MIL116 (also known as CLYM116) is Climb Bio's lead asset — an anti-APRIL monoclonal antibody in development for IgA nephropathy (IgAN), a chronic kidney disease with no cure. Phase 1 data presented at ASN Kidney Week 2026 showed a best-in-class ~33-day half-life, >90% APRIL suppression, and ~70% reduction in the key disease biomarker Gd-IgA1 with a single 800 mg dose, supporting a convenient every-12-week dosing regimen. The drug was well tolerated with no serious adverse events across 88 participants. The Phase 2 NAVIGATE-2 trial is enrolling IgAN patients with initial data expected in H1 2027, and a global Phase 3 trial is planned for 2027. Climb Bio trades on Nasdaq under CLYM at ~$10.19 with a ~$624M market cap, and analysts are overwhelmingly bullish (20 Buy/Strong Buy vs. 1 Hold) with a mean price target of $27.60, implying ~175% upside.
KRINTAFEL is the brand name for tafenoquine, an FDA-approved anti-malaria drug originally developed by GSK (approved July 2018). 60 Degrees Pharmaceuticals (NASDAQ: SXTP) is repurposing tafenoquine for babesiosis, a tick-borne disease with no FDA-approved treatment. The company has 30 patients randomized in a Phase 2 hospitalized babesiosis study (NCT06207370) with blinded follow-up completing January 2027 — the next major binary catalyst. With a ~$3M market cap, going-concern risk, and this as essentially their only program, the stock is a high-risk binary bet on the babesiosis data. The drug itself is already approved and commercialized for malaria by GSK, but SXTP's value hinges entirely on label expansion into babesiosis.
PVRV-SF is Sinovac Biotech's purified Vero cell rabies vaccine that received NMPA marketing approval in China on August 4, 2026. While this is a positive pipeline milestone adding a new commercial vaccine to Sinovac's portfolio, the company's stock (SVA) has been halted on Nasdaq since February 2019 with no active trading market. Sinovac faces severe financial distress (widening losses, cash burn, drained retained earnings), a governance crisis (contested board, no shareholder meetings since 2018), and regulatory limbo (Nasdaq Mandatory Panel Monitor through May 2027). The NMPA approval does not address these fundamental issues, and the stock remains untradeable for investors.
FemaSeed is Femasys Inc.'s FDA-cleared, commercially available fertility treatment device — a catheter-based system for intrauterine insemination (IUI) that enables OB/GYNs to perform in-office fertility procedures. Already on the market, FemaSeed faces a slow commercial ramp with the company reporting only ~$757K in total H1 2026 product revenue across its entire portfolio. The key near-term catalyst is Category III CPT reimbursement coverage effective January 2027, which could drive adoption. However, Femasys is a micro-cap ($7M market cap) with heavy dilution from a recent $30M private placement (with warrants for up to $90M more), a 1-for-20 reverse stock split in June 2026, and a cash burn rate that consumed $7.8M in H1 2026. The stock trades near $2.78, down ~67% from its 200-day SMA, with analyst price targets implying ~260% upside but the core business is deteriorating.
-
nimacimab is a peripherally restricted CB1 receptor inverse agonist (a 'blocker of the munchies receptor' that avoids brain side effects) being developed by Skye Bioscience (SKYE) for obesity. Phase 2a data showed a compelling 22.3% mean weight loss at 52 weeks in combination with semaglutide, and a Part C dose-expansion study is underway with topline data expected Q4 2026. However, Skye announced a transformative reverse merger with Redx Pharma (Aug 14, 2026) that will dilute existing shareholders to ~5.38% ownership of the combined Fibrx Therapeutics entity. nimacimab is being monetized separately via Contingent Value Rights (CVRs) entitling SKYE shareholders to 90% of net proceeds within 12 months of deal close. With cash runway only through Q4 2026, heavy insider selling, and the stock down ~95% from its 52-week high of $39.92, nimacimab's value to SKYE shareholders is now tied primarily to the CVR — making the fundamental thesis highly speculative and diluted.
Explore drug → -
RXC008 is a fibrosis drug candidate from private UK biotech Redx Pharma, which is being acquired by Skye Bioscience (SKYE) in a reverse merger that will form a new entity called Fibrx Therapeutics. The combined company has secured $125M in committed financing to advance RXC008 through Phase 2 topline data expected in H2 2028. However, pre-transaction Skye shareholders will own only ~5.38% of the combined company, representing extreme dilution. The drug is still in early-to-mid stage development with no near-term binary catalyst, and the reverse merger structure heavily disadvantages current SKYE holders.
Explore drug →
NMRA-511 is Neumora Therapeutics' Phase 1b/2a asset for Alzheimer's disease agitation, a vasopressin V1a receptor antagonist. Phase 1b data showed encouraging signals (Cohen's d 0.34 on CMAI total score, 0.51 on aggression sub-factor). The next catalyst is MAD expansion cohort data expected in Q4 2026, with a Phase 2 start planned by end of 2026. Neumora (NMRA) trades at ~$1.04 with $116.8M cash (runway into Q3 2027) and a market cap of ~$320M. While NMRA-511 is a promising pipeline asset, it is not the company's lead program (navacaprant for MDD is more advanced), and the stock faces headwinds from insider selling, cash burn, and the binary risk of early-stage clinical readouts.
Ibezapolstat is Acurx Pharmaceuticals' lead (and essentially only) drug candidate — a novel oral antibiotic for C. difficile infection that works by a new mechanism (DNA polymerase IIIC inhibition). The company received FDA guidance supporting a single Phase 3 pivotal trial, which is a positive regulatory signal, but the trial has not yet begun. ACXP is a micro-cap pre-revenue biotech trading at ~$1.40 with a ~$6.4M market cap, a going concern audit opinion, and only ~9 months of cash runway. Analysts are extremely bullish (8 Buy/Strong Buy vs 1 Hold, mean PT $17 implying 614% upside), but the stock has fallen 72% over 6 months, institutions are trimming, and the company relies on a dilutive equity line for funding. The drug's novel mechanism and FDA alignment are real positives, but the financing overhang and binary Phase 3 execution risk make this a high-risk, high-reward proposition with no near-term hard catalyst.
DARE to PLAY is a branded sildenafil topical cream for female sexual dysfunction, developed by Daré Bioscience (DARE, Nasdaq). Unlike a traditional FDA-approved drug, it is a compounded prescription product that can be dispensed through pharmacies without a lengthy regulatory approval process. The company expects dispensing and initial revenue to begin in Q3 2026 (the current quarter). While the product addresses a large unmet need in women's health and analysts are overwhelmingly bullish (8 Buy/Strong Buy, 1 Hold; mean PT $8.33 vs ~$0.70 stock), Daré Bioscience is in severe financial distress — cash has burned from $24.7M to $12.6M, working capital is negative, the company faces Nasdaq delisting risk, and a dilutive S-1 registration went effective in September 2026. DARE to PLAY is one of several pipeline assets (alongside Ovaprene Phase 3 and DARE-HPV Phase 2), but the company's survival likely hinges on generating near-term product revenue.
CLD-501 is a preclinical-stage systemic oncolytic virotherapy from Calidi Biotherapeutics (CLDI), part of the company's RedTail platform that delivers a T-cell engager payload directly into tumors. It is a secondary program behind the lead candidate CLD-401 (IL-15 superagonist), which itself is still in IND-enabling studies. Two preclinical abstracts on the RedTail platform (including CLD-501) were accepted for the 2026 ASCO Annual Meeting, but no human clinical data exist. Calidi has a ~$4M market cap, only $4.1M cash, a going-concern warning, and no approved products — making CLD-501 a very early, high-risk, long-duration option with no near-term catalyst.
Joenja (leniolisib) is an oral PI3K delta inhibitor approved as the first treatment for Activated PI3K Delta Syndrome (APDS), an ultra-rare primary immunodeficiency. Originally approved by the FDA in March 2023 for patients 12+, Pharming has steadily expanded the label: EU approval (May 2026), Japan approval/launch (March/August 2026), and most recently FDA approval for children aged 4-11 (September 11, 2026). Joenja generated $17.9M in Q2 2026 (40% YoY growth) and is the company's growth engine, though the larger RUCONEST franchise is declining. The stock trades at ~$11.21 with a mean analyst target of $34.35 (234% implied upside) and a consensus of 13 out of 14 analysts at Buy/Strong Buy.
Ameluz (aminolevulinic acid HCl gel / BF-200 ALA) is Biofrontera Inc.'s (Nasdaq: BFRI) lead commercial product — a topical photosensitizer used in photodynamic therapy (PDT) for dermatological conditions. It is already FDA-approved for actinic keratosis (AK) and generating growing revenue ($12M in Q2 2026, +33% YoY), with the company nearing cash-flow breakeven. The critical near-term catalyst is the FDA PDUFA date of September 28, 2026, for a supplemental NDA seeking approval for superficial basal cell carcinoma (sBCC). Analyst consensus is strongly bullish (7 Buy/Strong Buy vs 1 Hold) with a mean price target of $6, implying ~287% upside from the current ~$1.55 share price. Risks include limited cash ($4.7M), an ITC exclusion order on the companion RhodoLED lamp, and the binary nature of the pending FDA decision.
Halneuron is Dogwood Therapeutics' lead drug candidate for chemotherapy-induced neuropathic pain (CINP), a condition with no FDA-approved treatments. It is currently in a Phase 2b double-blinded trial with positive interim data showing separation from placebo, and top-line results are expected imminently in fall 2026. The drug received FDA Fast Track designation in May 2026. Dogwood Therapeutics (DWTX) is a ~$62M market cap pre-revenue biotech with cash runway only through Q4 2026, making the Phase 2b readout a potential make-or-break binary catalyst. Analyst consensus is strongly bullish (7 analysts: 2 Strong Buy, 5 Buy, 1 Hold) with a mean price target of $14 (673% upside), but the company's cash burn, $9.2M impairment charge, and lack of approved products create significant downside risk if the trial fails.
CTx-1301 is Cingulate Inc.'s lead and only pipeline asset — a proprietary extended-release formulation of dexmethylphenidate (the active ingredient in Focalin XR) for ADHD, delivered via the company's Precision Timed Release (PTR) technology. A Phase 3 trial in adults completed successfully, and the NDA was accepted for FDA review with a May 31, 2026 PDUFA date. However, on June 1, 2026, the FDA issued a Complete Response Letter (CRL) citing only Chemistry, Manufacturing, and Controls (CMC) deficiencies — no clinical safety or efficacy issues were raised. Cingulate is working on CMC remediation and NDA resubmission, but has not provided a specific timeline. The stock trades at ~$5.02, far below the mean analyst price target of $21.20, reflecting the regulatory overhang. The company has ~$28.4M in cash (runway into mid-2027) and recently secured a U.S. patent through 2042 and a distribution agreement with Prasco.
GTx-101
Sep 12, 2026GTx-101 is a topical bioadhesive film-forming polymer spray formulation of bupivacaine that was being developed by Grace Therapeutics (GRCE) for pain associated with postherpetic neuralgia (PHN). The drug completed Phase 1 studies and a PK bridging study that met its primary endpoints. However, in Q1 FY2027 (quarter ending June 30, 2026), Grace Therapeutics formally discontinued GTx-101 (along with GTx-102), recording a $13.5M impairment of IPR&D. The company has pivoted entirely to its lead asset GTx-104 (IV nimodipine for aSAH), which received a CRL from the FDA in April 2026. GTx-101 is effectively a dead program with no remaining catalysts.
YORVIPATH (palopegteriparatide, developed as TransCon PTH) is a once-daily parathyroid hormone replacement therapy approved by the FDA in August 2024 as the first and only treatment for hypoparathyroidism in adults. Developed by Ascendis Pharma (Nasdaq: ASND), the drug uses the company's TransCon prodrug technology to deliver continuous PTH exposure. YORVIPATH has seen a rapid commercial launch with Q2 2026 revenue of €252 million (up 145% YoY from €103M), is available in over 35 countries, and has enrolled more than 5,300 U.S. patients. With the only prior competitor (NATPARA) discontinued, YORVIPATH holds a market monopoly in a rare disease with no other approved alternatives.
iopofosine I 131 (CLR 131) is Cellectar Biosciences' lead radiopharmaceutical candidate targeting Waldenström macroglobulinemia and other B-cell malignancies. Phase 2b CLOVER WaM data showed a 83.6% overall response rate and 61.8% major response rate with median duration of response of 17.8 months, supporting a planned accelerated approval NDA submission to the FDA in mid-2027. The company has initiated site activation for a Phase 3 confirmatory trial. With a ~$21M market cap, $34M cash runway into Q2 2027, and analyst price targets implying ~354% upside, the stock is a high-risk/high-reward binary play on regulatory success. However, significant dilution from the May 2026 offering and the need for additional capital before any revenue materializes are key risks.
Tinlarebant is Belite Bio's lead drug candidate — an oral RBP4 antagonist targeting Stargardt disease (STGD1), a rare inherited retinal disease with no approved treatments. The Phase 3 DRAGON trial met its primary endpoint, and the FDA accepted the NDA with Priority Review, setting a PDUFA target action date of February 12, 2027. The company also has ongoing trials in geographic atrophy (PHOENIX, Phase 3, 530 subjects enrolled) and a second STGD1 trial (DRAGON II, Phase 2/3, 73 subjects enrolled). With a ~$7B market cap, strong institutional backing, ~$780M cash position, and a Strong Buy analyst consensus (mean target $227), the stock's near-term trajectory hinges entirely on the February 2027 PDUFA decision.
Emrosi™ is an FDA-approved prescription topical foam treatment for inflammatory lesions of rosacea in adults, developed and commercialized by Journey Medical Corp (Nasdaq: DERM). Approved around November 2024, Emrosi is already generating meaningful revenue — $14.7M in FY2025, growing to $8.1M in Q2 2026 alone — and has secured payer access covering ~85% of U.S. commercial lives. The drug is the primary growth driver for Journey Medical, which has posted two consecutive quarters of positive Adjusted EBITDA. With a strong analyst consensus (9 Buy/Strong Buy, mean price target $13.75 vs ~$7.23 current) and accelerating prescription trends, Emrosi represents the core value driver for this small-cap dermatology company.
ANB033 is a clinical-stage antibody therapeutic being developed by First Tracks Biotherapeutics (Nasdaq: TRAX) for celiac disease, with an additional program in eosinophilic esophagitis. The company was spun off from AnaptysBio in April 2026 with $100M in cash and a $180M total cash position at launch. ANB033 is the lead pipeline asset and has received FDA Fast Track designation for celiac disease. The next major catalyst is Cohort 1 Phase 1b data readout expected in Q4 2026 (within ~3 months). The company has $168M in cash (as of June 30, 2026) with runway into Q2 2028. Analyst consensus is Strong Buy with a mean price target of $69.44, implying ~78% upside from the current ~$36.44 price. The stock is a binary event-driven play on the Phase 1b data.
-
ATR-12 is Azitra's Phase 1b drug candidate for Netherton Syndrome, a rare genetic skin disorder. However, the company paused enrollment in the ATR-12 trial in June 2026 to conserve capital and redirect limited funds toward its cosmetic ingredient program (ATR-COSF) and ATR-04 (EGFRi-associated rash). With only ~$6.7M in cash, a ~$2-3M market cap, a going concern opinion, and massive potential dilution from an S-1 covering 255.7M shares (526% of outstanding), ATR-12 is effectively on ice with no near-term catalyst. The stock trades around $0.18, down ~77% over 12 months.
Explore drug → -
ATR-04 (ATR04-484) is Azitra's topical live biotherapeutic product candidate for treating moderate-to-severe skin rash caused by EGFR inhibitor cancer therapy. It uses an engineered auxotrophic strain of Staphylococcus epidermidis (SE484) designed to reduce inflammation (IL-36g) and inhibit S. aureus. The FDA granted Fast Track designation in March 2026. A Phase 1/2 randomized, double-blind, vehicle-controlled trial began dosing in August 2025, with topline data from the first cohort expected in Q4 2026. Azitra (NYSE American: AZTR) is a micro-cap clinical-stage biopharma with ~$6.7M cash, a ~$2.3M market cap, and roughly 6 months of runway — the ATR-12 Netherton Syndrome study was paused to conserve cash. Analyst consensus is bullish (6 Buy/Strong Buy, 1 Hold) with a mean price target of $0.775 (~335% upside), but the cash burn and dilution risk are significant.
Explore drug →
Firmonertinib is ArriVent BioPharma's (AVBP, Nasdaq) lead drug candidate — an oral EGFR inhibitor targeting exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company has completed enrollment in the pivotal Phase 3 FURVENT trial and expects topline data in 2H 2026. This is a make-or-break catalyst for a pre-revenue biotech with no approved products. Analyst sentiment is strongly bullish (17 Buy/Strong Buy, mean PT $44.70 vs ~$29 stock), but the binary risk is extreme — trial failure would be devastating. High short interest (~17.6% of outstanding, 20+ days to cover) adds squeeze potential on positive data but also reflects skepticism. The company has ~$326M cash (funding into Q4 2027) and an ATM facility for up to $250M in additional capital.
Proclarix is a CE-marked blood-based diagnostic test for prostate cancer being commercialized in Europe by Onconetix, Inc. (ONCO), a micro-cap biotech company in severe financial distress. The company has a going concern warning, ~$5.1M in cash, a ~$3M market cap, and is pivoting to AI/humanoid robotics via a pending all-stock acquisition of Realbotix LLC. Proclarix is a legacy asset with no near-term binary catalyst — the PRIME study with Labcorp for US market entry is ongoing but has no announced readout date. The stock is primarily driven by extreme dilution risk (an S-1 effective for up to 100M shares of resale, representing ~2,282% of outstanding) and the Realbotix deal timeline, not by Proclarix's commercial progress.
APR-1051 is Aprea Therapeutics' lead asset, an oral next-generation WEE1 kinase inhibitor in a first-in-human Phase 1 trial (ACESOT-1051, NCT06260514) for advanced solid tumors. Early data presented at ASCO 2026 showed a manageable safety profile with preliminary signals of antitumor activity, including two partial responses in biomarker-defined cancers. Enrollment is accelerating with sites expanding from 3 to 10, and the next clinical data update is expected in Q4 2026. Aprea is a micro-cap (~$10M market cap, stock ~$0.77) with strong analyst support (mean price target $3.73) and cash runway into Q1 2028, but faces significant risks from early-stage clinical development, massive warrant dilution (89.4M warrants vs 12.6M shares), and a competitive WEE1 inhibitor landscape.
ADG126 (muzastotug) is Adagene Inc.'s lead clinical asset and a 'masked' anti-CTLA-4 antibody using the company's proprietary SAFEbody platform. It aims to improve upon existing CTLA-4 inhibitors by activating only in the tumor microenvironment, potentially offering better safety and higher dosing. Phase 1b/2 data have shown promising response rates in MSS colorectal cancer (31-36% ORR at 20 mg/kg with Keytruda) and in first-line liver cancer (66.7% ORR triple combination). A randomized Phase 2 in MSS CRC is the key upcoming catalyst, with results expected in H1 2027. The company is well-capitalized with $127.9M cash running into late 2028 and has attracted partnerships with Sanofi and Incyte. The stock trades at ~$3.30 with strong analyst support (10 analysts: 10 Buy/Hold, 0 Sell; mean PT $10.09, implying ~205% upside). Key risks include clinical trial failure, dilution from the April 2026 $70M offering (42% share increase), and competition from other CTLA-4 agents.
Vidofludimus calcium (IMU-838) is Immunic's sole late-stage asset — an oral, next-generation DHODH inhibitor in Phase 3 (ENSURE trials) for relapsing multiple sclerosis. The company raised $200M via a PIPE in early 2026, ending Q2 with $155.1M cash to fund operations into late 2027. Top-line Phase 3 data is expected by year-end 2026, with NDA submission targeted for mid-2027. Analyst consensus is strongly bullish (17 positive ratings vs 1 hold), with a mean price target of $43.09 — implying ~146% upside — though covering firms have below-average track records. Two notable new institutional holders (Millennium Management, Aberdeen Group) appeared in Q2 2026. This is a high-conviction, single-asset binary: success could launch a major new oral MS therapy; failure would leave the company with no late-stage pipeline.
Barostim is CVRx's FDA-approved implantable baroreflex activation therapy (BAT) device for NYHA Class III heart failure. Already approved since 2019 and commercially marketed, Barostim is CVRx's sole product. The stock has fallen ~76% from its 52-week high of $11.30 to ~$2.83, reflecting slow commercial uptake and ongoing operating losses (Q1 2026 EPS -$0.50). Analysts see ~59% upside to a $4.58 mean target but the stock is deeply out of favor. Insider buying and some institutional accumulation (Renaissance, UBS, JPMorgan) provide bull signals, but the company has no near-term binary catalyst and faces the classic challenge of driving physician adoption and reimbursement for a novel surgical heart-failure therapy.